21 July, 2016 DURBAN - The Drugs for Neglected Diseases initiative (DNDi) announced a new and better treatment for children living with HIV, which could be available by the end of 2018. The new 4-in-1 formulation, in the form of pellets, is more tolerable, better tasting, safer for children to use and does not require refrigeration. It will replace a liquid formulation being used to treat children living with HIV that had high alcohol content, and tasted bitter.
GENEVA, 20 July, 2016 - A report by Médecins Sans Frontières (MSF) provides invaluable guidance to countries seeking to make viral load testing routine for those on antiretroviral treatment, according to UNITAID Executive Director Lelio Marmora.
PUBLIC RECOGNITION AWARD
Highlighting Exceptional Efforts to Increase Access to Children’s HIV/AIDS Treatment
29 June 2016
PARIS - UNITAID has committed up to US $2.45 million to support a trial of the new-generation anti-HIV drug dolutegravir as a first-line treatment for HIV in low-income settings. The trial, which will take place in Cameroon, aims to gather evidence on the potential benefits of dolutegravir in a low-income setting.
Geneva, 3 June 2016. Ministers of Health from more than 30 countries gathered with national ambassadors and UNITAID partners in Geneva, Switzerland, on 22 May 2016 to celebrate 10 years of UNITAID’s work. They discussed the organisation’s successes as well as challenges for the future. The ministers also shared ideas about their national policies for HIV, malaria and tuberculosis.
GENEVA, 22 March 2016 – Today UNITAID published an updated “disease narrative” for tuberculosis – a rigorous analysis of the context surrounding the disease – to help guide its investments.
A primary goal of UNITAID is to identify how it can best contribute to the global response with carefully targeted investments that help, for example, to overcome specific obstacles such as high prices for medicines that show promise.
These “areas for intervention”, pinpointing where UNITAID’s investments can most effectively help advance global health goals to end tuberculosis, are the building blocks of our work. They also enable our partners to achieve more with scarce resources.
Geneva, 27 November 2015: UNITAID today released its 2015 HIV/AIDS Diagnostics Technology Landscape that summarizes the latest products and technologies to detect, stage and monitor HIV infection. The Landscape covers technologies including instruments for laboratories, multi-purpose platforms and innovations at points of care to diagnose infants and to monitor viral load and CD4.
26 February 2015 - Global health partners met in Geneva to begin the process of building a new approach to better determine health needs and constraints and addressing them in countries.
The new framework, the Equitable Access Initiative, aims to better inform international decision making processes on health and development, particularly where they rely on traditional gross-national-income classification as a measure of where to invest global health resources.
UNITAID signs grant with MSF to spur action
Geneva. 12 February 2015 - UNITAID’s newly published analysis on the rapidly changing medicines market for hepatitis C [PDF, 2 MB] indicates four routes by which recently developed but currently prohibitively expensive medicines can be made affordable and available for widespread use. There are up to 150 million infected worldwide with this curable disease, and up to 700,000 deaths each year from related liver disease. The new medicines could be game-changers for the fight against the disease if made widely available. UNITAID has already started working with Médecins Sans Frontières (MSF) to demonstrate the feasibility of treating hepatitis C with these new medicines in resource limited settings, including through reducing prices.
Diagnosis and screening currently too complex and expensive, but new options emerging
Geneva – January 2014. UNITAID’s review of testing technologies for hepatitis C (HCV) published today, finds that although current diagnosis and screening options for the disease remain too complex and expensive for widespread scale up, there are some emerging technologies which could change this situation. The new report, Hepatitis C Diagnostics Technology Landscape [PDF, 4 MB], follows an initial scoping report released in 2013 that explored the many issues and challenges related to HCV treatment and diagnosis. The new landscape report identifies several simpler tests which will enable diagnosis and monitoring closer to the point-of-care with the patient. Some of these are expected to reach the market later this year.
- New Vector Control Products Urgently Needed to Combat Insecticide Resistance, UNITAID Report Warns
- UNITAID Finds Affordability, Availability and Demand Slow Access to HIV Prevention Products
- UNITAID’s EXPAND-TB and TBXpert MTB-RIF Projects Detect Over A Quarter of all MDR-TB Cases
- Support Builds For Japan’s Adoption of the Air Ticket Levy at the Terashima Commission
- UNITAID Tuberculosis Medicines Technology and Market Landscape (Second Edition)